Adaptive Biotechnologies posts Q2 2026 revenue growth, plans Immune Medicine separation
The company raised full-year MRD revenue guidance and disclosed a $345 million convertible notes deal alongside a leadership change for co-founder Harlan Robins.
SEC filing